The protective effects of CD39 overexpression in multiple low-dose streptozotocin-induced diabetes in mice

Diabetes

Volumn 62, Issue 6, 2013, Pages 2026-2035

  Chia, Joanne S J ^a,b   McRae, Jennifer L ^a   Thomas, Helen E ^c   Fynch, Stacey ^c   Elkerbout, Lorraine ^c   Hill, Prue ^a   Murray Segal, Lisa ^a   Robson, Simon C ^d   Chen, Jiang Fan ^e   D'Apice, Anthony J F ^a,b   Cowan, Peter J ^a,b   Dwyer, Karen M ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; CD39 ANTIGEN; PSB 1115; PSB 36; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; GENE OVEREXPRESSION; GRAFT REJECTION; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD; APYRASE; DIABETES MELLITUS, EXPERIMENTAL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PURINERGIC P1;

EID: 84878218001     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0625     Document Type: Article

References (50)

1. Yasunami Y, Kojo S, Kitamura H, et al. Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J Exp Med 2005;202:913-918 (Pubitemid 41398198)
2. Azzi J, Geara AS, El-Sayegh S, Abdi R. Immunological aspects of pancreatic islet cell transplantation. Expert Rev Clin Immunol 2010;6:111-124
3. Petruzzo P, Andreelli F, McGregor B, et al. Evidence of recurrent type I diabetes following HLA-mismatched pancreas transplantation. Diabetes Metab 2000;26:215-218 (Pubitemid 30435768)
4. Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001;50:2464-2471 (Pubitemid 33642763)
5. Vantyghem MC, Fajardy I, Pigny P, et al. Kinetics of diabetes-associated autoantibodies after sequential intraportal islet allograft associated with kidney transplantation in type 1 diabetes. Diabetes Metab 2003;29:595-601 (Pubitemid 38082161)
6. Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes 1989;38(Suppl 1):85-87 (Pubitemid 19029246)
7. Tydén G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med 1996;335:860-863 (Pubitemid 26304068)
8. Okitsu T, Bartlett ST, Hadley GA, Drachenberg CB, Farney AC. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am J Transplant 2001;1:138-145 (Pubitemid 33674153)
9. Markees TG, Serreze DV, Phillips NE, et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 1999;48:967-974 (Pubitemid 29226341)
10. Makhlouf L, Kishimoto K, Smith RN, et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes 2002;51:3202-3210 (Pubitemid 35246966)
11. Dwyer KM, Mysore TB, Crikis S, et al. The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation 2006;82:428-432 (Pubitemid 44223045)
12. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004;113:1440-1446 (Pubitemid 39071699)
13. Inverardi L, Ricordi C. Therapeutic approaches to counteract immediate blood-mediated inflammatory reaction in islet transplantation. Transplantation 2006;82:312-313 (Pubitemid 44223027)
14. Lin M, Yin N, Murphy B, et al. Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin. Diabetes 2010;59:2247-2252
15. Zimmermann H. Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis. Nat Med 1999;5:987-988 (Pubitemid 29439562)
16. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-770
17. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008;1783:673-694
18. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010;10:2586-2595
19. Németh ZH, Bleich D, Csóka B, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007;21:2379-2388 (Pubitemid 47230668)
20. Enjyoji K, Sévigny J, Lin Y, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999;5:1010-1017 (Pubitemid 29439571)
21. Chen JF, Huang Z, Ma J, et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999;19:9192-9200 (Pubitemid 30228071)
22. Leiter EH. Multiple low-dose streptozotocin-induced hyperglycemia and insulitis in C57BL mice: influence of inbred background, sex, and thymus. Proc Natl Acad Sci USA 1982;79:630-634 (Pubitemid 12137765)
23. Mottram PL, Han WR, Murray-Segal LJ, Mandel TE, Pietersz GA, McKenzie IF. Idarubicin-anti-CD3: a new immunoconjugate that induces alloantigen-specific tolerance in mice. Transplantation 1997;64:684-690 (Pubitemid 27407093)
24. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-622
25. Enjyoji K, Kotani K, Thukral C, et al. Deletion of cd39/entpd1 results in hepatic insulin resistance. Diabetes 2008;57:2311-2320
26. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-1265 (Pubitemid 46919862)
27. McEvoy RC, Andersson J, Sandler S, Hellerström C. Multiple low-dose streptozotocin-induced diabetes in the mouse. Evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest 1984;74:715-722 (Pubitemid 14031006)
28. Pommey, S, Lu, B, McRae, J, et al. 2012. Liver grafts from CD39-overexpressing mice are protected from ischemia reperfusion injury due to reduced numbers of resident CD4(+) T cells. Hepatology. 24 July 2012 [Epub ahead of print]
29. Andersson O, Adams BA, Yoo D, et al. Adenosine signaling promotes regeneration of pancreatic β cells in vivo. Cell Metab 2012;15:885-894
30. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54:2060-2069 (Pubitemid 40911269)
31. Figler RA, Wang G, Srinivasan S, et al. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes 2011;60:669-679
32. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005;54(Suppl. 2):S97-S107 (Pubitemid 43343337)
33. Kutlu B, Naamane N, Berthou L, Eizirik DL. New approaches for in silico identi fication of cytokine-modified beta cell gene networks. Ann N Y Acad Sci 2004;1037:41-58 (Pubitemid 40299741)
34. Annes JP, Ryu JH, Lam K, et al. Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication. Proc Natl Acad Sci USA 2012;109:3915-3920
35. Lavoie EG, Fausther M, Kauffenstein G, et al. Identification of the ectonucleotidases expressed in mouse, rat, and human Langerhans islets: potential role of NTPDase3 in insulin secretion. Am J Physiol Endocrinol Metab 2010;299:E647-E656
36. Künzli BM, Berberat PO, Giese T, et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol 2007;292:G223-G230 (Pubitemid 46098885)
37. Kukulski F, Lévesque SA, Sévigny J. Impact of ectoenzymes on p2 and p1 receptor signaling. Adv Pharmacol 2011;61:263-299
38. Fausther M, Lecka J, Soliman E, et al. Coexpression of ecto-5′-nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Am J Physiol Gastrointest Liver Physiol 2012;302:G447-G459
39. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol 2005;5:760-771 (Pubitemid 41400850)
40. Ålgars A, Karikoski M, Yegutkin GG, et al. Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 2011;117:4387-4393
41. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal 2006;2:351-360
42. Kinsey GR, Huang L, Jaworska K, et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 2012;23:1528-1537
43. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol 2006;177:6780-6786 (Pubitemid 44715042)
44. Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994;46:143-156 (Pubitemid 24984777)
45. Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol 2006;176:3108-3114
46. Day YJ, Huang L, Ye H, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol 2005;288:F722-F731 (Pubitemid 40381739)
47. Grenz A, Zhang H, Hermes M, et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007;21:2863-2873 (Pubitemid 47372753)
48. Moriyama K, Sitkovsky MV. Adenosine A2A receptor is involved in cell surface expression of A2B receptor. J Biol Chem 2010;285:39271-39288
49. Chhabra P, Wang K, Zeng Q, et al. Adenosine A(2A) agonist administration improves islet transplant outcome: evidence for the role of innate immunity in islet graft rejection. Cell Transplant 2010;19:597-612
50. Nitta T, Itoh T, Matsuoka N, et al. Prevention of early loss of transplanted islets in the liver of mice by adenosine. Transplantation 2009;88:49-56